Money Control -- Strides Arcolab received a nod by the US FDA for an Oncology unit in Bengaluru. Arun Kumar, group CEO and vice chairman of Strides Arcolab, in an exclusive interview with CNBC-TV18 shares that the company expects approvals on approximately USD 4-5 billon product filings with the US FDA over the next few weeks.
40 oncology drugs have been out licensed to Pfizer, and Kumar further confirms that the Pfizer partnership is the most impactful. He also says that this approval allows the company to operate in a niche space within US.
